AbbVie and Genmab's epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, the first Phase 3 win for a bispecific combination in the frontline setting.
October 6, 2026Vaxcyte's 31-valent pneumococcal conjugate vaccine met all primary immunogenicity endpoints in the OPUS-1 Phase 3 trial, positioning it to challenge Pfizer's Prevnar 20 and Merck's Capvaxive. Shares closed up 31%.
October 6, 2026ArriVent's firmonertinib missed the Phase 3 FURVENT primary endpoint in first-line EGFR exon 20 NSCLC, sending shares down 47% to $15.09.
October 6, 2026 · oncology · $AVBPAstraZeneca is making a $2 billion equity investment in Summit Therapeutics and teaming up to test ivonescimab with its ADC portfolio, a major validation of the PD-1/VEGF bispecific ahead of its November PDUFA.
September 29, 2026ASCO GI 2027 is the first oncology catalyst window of the year. Screen these five GI-cancer datasets on January 19, the day full abstracts drop. Here is why.
September 29, 2026The FDA accepted Alexion's BLA for efzimfotase alfa and granted Priority Review for hypophosphatasia in patients 2 and older. A decision is expected in H1 2027.
September 29, 2026Adicet Bio reported that 54% of patients in its Phase 1 lupus study met DORIS remission at 12 months, a first durability print for an allogeneic CAR-T.
September 28, 2026ASCO GU 2027 runs Feb 11-13 in San Francisco and abstract titles drop early January. Five GU names to screen, and the two small caps that re-rate 30%.
September 28, 2026Oclaiz's two CMC-only CRLs make the Dec 18 PDUFA a near-certain approval, but Vertex's $10B Palsonify bet means Camurus wins an injection war in a pill market.
September 28, 2026Both Zenkuda and KSI-501 met non-inferiority versus aflibercept in the DAYBREAK Phase 3 wet AMD trial, with 54% of Zenkuda patients on a 24-week dosing interval.
September 28, 2026 · Ophthalmology · $KODMirum's brelovitug hit the AZURE-1 primary endpoint in chronic hepatitis delta, with 56% of the weekly-dose arm achieving virologic response plus ALT normalization versus 0% on delayed treatment.
September 28, 2026 · Rare disease · $MIRMMerck licensed preclinical oral KRAS G12D(ON) inhibitor SPR2015 from China-based SciBrunch for $400 million upfront, in a deal worth up to $2.13 billion.
September 28, 2026FDA accepted Pharming's sNDA for lower-dose Joenja (leniolisib) in children 4+ weighing 13-27 kg with APDS, granting Priority Review. PDUFA is Jan 30, 2027.
September 28, 2026FDA approved Roche's Gazyva (obinutuzumab) to cut relapse risk for ages 2+ with frequently relapsing nephrotic syndrome. INSHORE hit 95.5% vs 73.2% remission.
September 28, 2026Every trader screens ASCO. The edge is SABCS, the Q4 breast meeting no one previews. Five ranked abstracts and the two names that actually re-rate 30%.
September 28, 2026SCYNEXIS (SCYX) won a BARDA contract worth up to $214M to advance antifungal SCY-247 through NDA submission. The committed base period is just $18.5M.
September 28, 2026AbbVie's Qulipta cut menstrual migraine days by 0.80 versus placebo in Phase 3 LUNA, the first CGRP-targeted drug to win specifically in this indication.
September 27, 2026The autoimmune CAR-T trade fires at abstract release in October, not the November 6-11 meeting. Five biotech names where one dataset re-rates shares 15-30%.
September 27, 2026Alexion's Klygefa, a once-weekly subcutaneous C5 inhibitor, won a CHMP recommendation for generalized myasthenia gravis. An EU decision follows in two months.
September 27, 2026The 2026 catalysts already resolved. 2027 rewards companies with a second shot on goal. Seven multi-shot platforms ranked by risk-reward, plus two avoids.
September 27, 2026The CTAD trade fires at abstract release in late October, not the November 16-19 meeting. Five biotech names where one dataset re-rates shares 15-30%.
September 27, 2026Immunovant ends IMVT-1402 in cutaneous lupus after the Phase 2 trial missed its CLASI-A endpoint at Week 12. Deeper IgG cuts still predicted response.
September 27, 2026ASCO moves oncology, ASH moves hematology, JPM moves deals. Six names with a 2027 catalyst and a cash runway or buyout question, ranked by deal-flow potential.
September 27, 2026The FDA accepted Nanoscope's BLA for MOGENRY, an optogenetic gene therapy for retinitis pigmentosa that bypasses the mutated gene. No decision date is set.
September 27, 2026Novo Nordisk's once-weekly Wegovy moved 40.4% of children aged 6 to 11 below the obesity threshold versus 0% on placebo in the Phase 3 STEP Young trial.
September 27, 2026The SITC trade fires at abstract release November 3, not the November 4-8 meeting in Phoenix. Five biotech names where one dataset re-rates shares 15-30%.
September 27, 2026Xenon filed its first NDA for azetukalner, a KV7 potassium channel opener for focal seizures, then paused psychiatry enrollment on a neuropsychiatric signal.
September 27, 2026The ASH 2026 trade fires at abstract release on November 4, not at the December 12-15 meeting. Five names where one dataset re-rates shares 15-30%. Here is why.
September 26, 2026Bristol Myers presented full Phase 3 EXCALIBER-RRMM data at IMS 2026: Zenbexus doubled the MRD-negative CR rate (41.1% vs 20.7%), but PFS is still pending.
September 26, 2026The FDA accepted Cogent's bezuclastinib NDA for advanced systemic mastocytosis, setting a June 29, 2027 PDUFA date as its third shot on goal for the drug.
September 26, 20262027's first half has 9 confirmed PDUFA dates. Five are investable binary events. Two are ghosts: one approved, one with no US ticker. Here is the playbook.
September 26, 2026CARVYKTI kept half of CARTITUDE-2 patients progression-free five years after one infusion. Median PFS hit 60.5 months and overall survival was not reached.
September 26, 2026The FDA approved Lilly's Olumiant for severe alopecia areata in patients 12 and up, the second oral JAK inhibitor for adolescents behind Pfizer's LITFULO.
September 26, 2026Lisata is reverse-merging with Marea and raising a $225M PIPE to advance MAR001, an anti-ANGPTL4 antibody in Phase 2b for severe hypertriglyceridemia.
September 26, 2026Novo will pay Nanexa up to $1.33B for its PharmaShell platform to develop monthly and quarterly GLP-1 injections. The $700M upfront is real near-term cash.
September 26, 2026Ignore GAAP EPS. Q3 earnings matter only when they carry a pipeline, guidance, or runway signal. Here are the 8 names and the one number to watch on each.
September 26, 2026REGENXBIO's sura-vec showed 60% of patients hit a two-step DRSS improvement at three years in diabetic retinopathy, extending its one-time gene therapy thesis.
September 26, 2026Roche's oral SERD, giredestrant, won adjuvant lidERA (HR 0.70) and evERA in ESR1-mutant disease (HR 0.38), but the franchise matters more than the stock.
September 26, 2026ATOMIC cut recurrence or death risk by 50% in stage III dMMR colon cancer (HR 0.50), but for Roche's CHF 262 billion ship the Oct 9 PDUFA is immaterial.
September 26, 2026The FDA accepted Takeda's zasocitinib NDA under Priority Review for plaque psoriasis. The once-daily oral TYK2 inhibitor challenges BMS's Sotyktu in 2027.
September 26, 2026Telix agreed to buy ITM for $1.65B upfront, up to $2.35B total, the largest radiopharma deal yet, adding the key 177Lu isotope supplier to its pipeline.
September 26, 2026FDA approves AbbVie's Juvmo (tavapadon) for Parkinson's, the first selective D1/D5 partial agonist to reach market. ABBV barely moved: it was priced in.
September 25, 2026 · Neuroscience · $ABBVAcadia missed RADIANT's primary endpoint (p=0.0603) but is advancing remlifanserin to Phase 3 in ADP anyway. A 0.26 effect size is what decides everything.
September 25, 2026The San Diego siRNA biotech raised $446.3M at $17 per share, the top of its $15-$17 range, with AbbVie buying a ~4.9% stake in a concurrent $100M placement. Total gross proceeds: ~$535.2M.
September 25, 2026 · RNAi / siRNA therapeutics · $ADRXDazodalibep hit its Phase 3 ESSDAI endpoint in Sjögren's, the first Horizon asset to win. But no magnitude disclosed and ianalumab ahead, the stock won't move.
September 25, 2026Arcturus reported safe, biomarker-improving Phase 2 data for ARCT-810 in OTC deficiency and unveiled LUNAR 2.0, plus a deal to acquire the AI firm myNEO.
September 25, 2026AstraZeneca's Etcamah missed the SERENA-4 first-line breast cancer endpoint, capping the oral SERD to the ESR1-mutant niche. Its accelerated approval is intact.
September 25, 2026FDA granted Priority Review to AstraZeneca's Imfinzi plus enfortumab vedotin for cisplatin-ineligible bladder cancer. A decision is expected in Q4 2026.
September 25, 2026Gossamer Bio filed its first NDA for seralutinib in PAH after a 1-for-80 reverse split. If the FDA accepts the filing, a decision could come in Q3 2027.
September 25, 2026A pre-PDUFA stock drops 40-60% on a CRL. Protective puts, collars, and covered calls to lock in your gains, and why trimming is usually the better move.
September 25, 2026JPM week in January isn't a data catalyst. It's the biotech deal-making and guidance week. Position for Jan 11-14, 2027 with this step-by-step framework.
September 25, 2026The CHMP recommended Incyte's Povofortay (povorcitinib), setting up the JAK1 inhibitor to become the first daily oral pill for hidradenitis suppurativa.
September 25, 2026ARIKAYCE's ENCORE data makes full approval highly likely. The real question is whether frontline MAC expansion moves revenue, and the stock already says yes.
September 25, 2026Ionis and Otsuka's ulefnersen met its primary endpoint in the Phase 3 FUSION trial in FUS-ALS (p=0.0005), the first placebo-controlled win for a therapy targeting the disease's genetic cause.
September 25, 2026 · Neurology · $IONSCaplyta's 4.8-point YMRS mania win turns J&J's $14.6B Intra-Cellular bet into a full-spectrum bipolar franchise, but the $643B stock won't move for investors.
September 25, 2026J&J said Tremfya hit its endpoints in the Phase 4 STAR study in axial psoriatic arthritis, the first IL-23 to show a spinal pain benefit in a dedicated trial.
September 25, 2026The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutant metastatic breast cancer. The combo doubled PFS to 11.1 months versus 5.5.
September 25, 2026The FDA approved Mirum's Atebrioz (zilurgisertib) for FOP in patients 12 and older, the third drug and first ALK2 inhibitor for the disease, cutting new bone volume 3.2 cm3 versus a 24.6 cm3 increase on placebo.
September 25, 2026 · Rare Disease · $MIRMMerck and Daiichi Sankyo withdrew the ifinatamab deruxtecan SCLC BLA after the FDA said Phase 2 data do not support accelerated approval. Oct 10 PDUFA is off.
September 25, 2026 · Oncology · $MRKFDA cleared belzutifan plus lenvatinib for advanced clear-cell renal cell carcinoma after PD-1/PD-L1 therapy on Sept 24, 2026, 10 days ahead of the Oct 4 PDUFA date.
September 25, 2026 · oncology · $MRKThe CHMP recommended EU approval of Novo Nordisk's Frehemgo (denecimig) for hemophilia A, even as the drug's July 29 US PDUFA decision stays unresolved.
September 25, 2026Enicepatide's 62% normoglycemia in Phase 2 T2D beats tirzepatide and retatrutide on glucose, but Roche is late, Phase 3 is years out, and RHHBY won't move.
September 25, 2026Spyre hit proof-of-concept on all three IBD mechanisms. Monotherapy data is in-line, not best-in-class; the real bet is the 2027 Part B combination readout.
September 25, 2026The FDA approved Telix's Pixclara (floretyrosine F 18), the first amino-acid PET imaging tracer to tell recurrent glioma apart from treatment-related change.
September 25, 2026Barzolvolimab met the primary and all key secondary endpoints in EMBARQ-CSU1 and CSU2 in chronic hives, but two anaphylaxis cases sent Celldex shares down about 12%.
September 24, 2026 · immunology · $CLDXElevar won its first FDA approval Sept 23 with Lyrfigtu, a selective FGFR2 inhibitor for advanced cholangiocarcinoma, entering an already-crowded niche third.
September 24, 2026An FDA panel voted 7-2 that GRAIL's Galleri multi-cancer blood test's benefits outweigh its risks, but split 6-4 on effectiveness. A final decision is next.
September 24, 2026 · diagnostics · $GRALIonis and Roche's sefaxersen met its IgAN Phase 3 endpoint, but Roche hid the proteinuria magnitude. Here's what that silence means for a $7.3B stock.
September 24, 2026Kyverna's CD19 CAR-T miv-cel held up at one year in stiff person syndrome, with a rolling BLA due Q4 2026. It could be the first CAR-T for autoimmune disease.
September 24, 2026FDA cleared Lilly's Onswik (insulin efsitora alfa-gobe) Sept 24 for type 2 diabetes, six months after Novo Nordisk's Awiqli opened the once-weekly basal insulin category.
September 24, 2026 · Cardiometabolic · $LLYRemigromig cleared BRUNELLO on non-inferiority to ranibizumab, but higher PDR and vitreous hemorrhage cloud AAO readout. Merck's $3B EyeBio bet is unsettled.
September 24, 2026Novo's CagriSema beat tirzepatide 5 mg on weight loss (12.4% vs 9.1%) in Phase 3, but the rival was dosed at its lowest marketed strength. The caveat matters.
September 24, 2026 · obesity · $NVOScholar Rock won FDA approval Sept 11 for ISEMBYLD, the first muscle-targeted SMA therapy, a myostatin inhibitor layered on top of existing SMN2 drugs.
September 24, 2026Ultragenyx won the first Sanfilippo type A approval Sept 17 with the AAV9 gene therapy FAYUVI, a one-time dose that earned a rare priority review voucher.
September 24, 2026VK2735 kept 90% of weight loss on monthly dosing and hit 22% placebo-adjusted loss. Viking priced a $500M raise into the rally. Buy the pullback, size it small.
September 24, 2026Inaxaplin cut proteinuria 42.7% in AMKD, but the type 2 diabetes cohort missed significance. The 466-patient AMPLITUDE interim in early 2027 is the real test.
September 24, 2026Sanofi killed its IL-33 drug; AstraZeneca's tozorakimab showed a 34% COPD exacerbation cut across every patient group. The $5B peak-sales call is now credible.
September 10, 2026The FDA granted accelerated approval to Bayer's sevabertinib (Hyrnuo) for first-line HER2-mutant NSCLC, the first HER2-directed therapy in the front-line setting. ORR hit 75% in SOHO-01.
September 10, 2026 · Oncology · $BAYRYThe FDA places a partial clinical hold on Biohaven's Kv7 epilepsy drug BHV-7000, pausing new enrollment in RISE 2 and RISE 3 over a rodent metabolite finding.
September 10, 2026 · Neuroscience · $BHVNNovo Nordisk halted HERMES and ATHENA, Phase 3 ziltivekimab trials, after a DSMB found futility. The ARTEMIS post-heart attack trial is the program's last shot.
September 10, 2026The FDA granted Priority Review to Enspryng for MOGAD, a rare CNS autoimmune disease with no approved treatments. PDUFA date is set for January 10, 2027.
September 10, 2026Roivant's inhaled mosliciguat posted the largest PVR reduction ever seen in a controlled PH trial. The Phase 3 PHrontier study will decide if it unseats Tyvaso.
September 10, 2026Tyra's SURF302 study of oral dabogratinib in bladder cancer showed 57% 3-month CR at 60 mg, missing the 70% bar, but single-lesion patients hit 100% ORR.
September 10, 2026Imdelltra plus Imfinzi met overall survival in Phase 3 DeLLphi-305 first-line maintenance SCLC — the first BiTE OS win in that setting.
September 9, 2026 · Oncology · $AMGNFDA granted accelerated approval to Etcamah (camizestrant) plus a CDK4/6 inhibitor — the first ctDNA-guided switch therapy in breast cancer.
September 9, 2026 · Oncology · $AZNBridgeBio filed its NDA for oral infigratinib in achondroplasia and showed the FGFR3 inhibitor improves sleep apnea and ear infections, not just height.
September 9, 2026BioMarin's Voxzogo hit its primary endpoint in the first hypochondroplasia Phase 3, improving growth velocity 2.33 cm/yr vs placebo, with filings due H2 2026.
September 9, 2026Bristol Myers Squibb's arlo-cel, a GPRC5D CAR-T, met its primary endpoint in the registrational QUINTESSENTIAL myeloma trial but withheld the response rate.
September 9, 2026The FDA accepted Intellia's lonvo-z for hereditary angioedema with Priority Review and a March 10, 2027 PDUFA date, advancing the first in vivo CRISPR therapy.
September 9, 2026Novartis' del-desiran missed the vHOT endpoint in HARBOR — the second late-stage miss in five days and a setback for the $12B Avidity deal.
September 9, 2026 · Neuromuscular · $NVSPelacarsen cut Lp(a) up to 80% but failed to reduce cardiovascular events in Lp(a)HORIZON — raising the bar for Lilly and Amgen rivals.
September 9, 2026 · Cardiovascular · $NVSAdicet's allogeneic CD20 CAR-T reads out in 22 lupus patients this month. At $88M, a clean 12-month print re-rates the stock; a safety stumble halves it.
September 4, 2026Mim8 is 43 business days past its July 29 PDUFA. The delay reads as labeling negotiation, not a CRL, and the real trade is Roche's Hemlibra franchise.
September 4, 2026A PDUFA date is a goal, not a deadline. Here's what happens when the FDA misses it, how to tell a CRL from a labeling delay, and what to do with your position.
September 4, 2026AbbVie's etentamig hit 74% ORR and cut progression risk 60% (HR 0.40) in Phase 3 CERVINO for triple-class exposed relapsed/refractory myeloma.
September 3, 2026 · Oncology · $ABBVSix drugs won FDA approval in July-August 2026. Only two moved the stock. Here is the launch report card, ranked from highest conviction to rounding error.
September 3, 2026ESMO 2026 runs Sept 17-21 in Madrid and abstracts drop mid-September. Five mid-cap names where one dataset could re-rate shares 15-30% before the presentation.
September 3, 2026GU oncology is the one cancer subsector where approvals expand the addressable population, not reshuffle share. Here is how to rank the next three catalysts.
September 3, 2026GSK paid $110M upfront for HUTCHMED's preclinical KRAS-EGFR ATTC. The $1.3B headline is milestone math. For HUTCHMED it's validation; for GSK it's immaterial.
September 3, 2026Most biotech insider selling is noise. Learn the 5-question checklist that separates pre-scheduled 10b5-1 plans from the bearish patterns short sellers track.
September 3, 2026FDA approved Zanvastro for Alexander disease — the first treatment for the fatal GFAP-driven disorder. Ionis banked a rare-disease PRV.
September 3, 2026 · Neurology · $IONSPfizer licenses its shelved Seagen ADC PF-08046031 to Medicus Pharma for $12M upfront plus up to $1B in milestones; MDCX fell 34% on the dilution risk.
September 3, 2026CGRP drugs are a $5 billion market consolidating around AbbVie's oral franchise. The next wave, PACAP targeting, is where the binary upside lives for investors.
September 3, 2026Everyone sells biotech into December. That is when to buy. Four tax-loss washout names, nine PDUFA dates ranked, and the sizing rules that keep you solvent.
September 3, 2026Apazunersen missed its primary cognition endpoint in Angelman syndrome, erasing nearly half of Ultragenyx's market value overnight.
September 3, 2026 · Rare Disease · $RAREAkeso's HARMONi-2 hit overall survival at interim, making ivonescimab dual-positive on PFS and OS versus Keytruda. Summit surged.
September 3, 2026 · Oncology · $SMMTTagrisso plus Orpathys beat Tagrisso alone on progression-free survival in China's 326-patient SANOVO trial for MET-overexpressing EGFR-mutant lung cancer.
September 2, 2026Warrants, pre-funded warrants, and convertible notes are dilution that hasn't hit the share count yet. Here is the math that reveals the full overhang.
September 2, 2026BioMarin collects 20% on Ascendis weekly achondroplasia drug through 2030. That is roughly $720M by 2030, but it recovers only 20 cents per lost Voxzogo dollar.
September 2, 2026 · Rare Disease · $BMRNTwo channels move a drug to the patient; the channel, not the price, decides launch margins and revenue timing. How buy-and-bill and pharmacy benefit work.
September 2, 2026A CVR is a contingent right to future cash if a milestone hits, and most of them expire worthless. How to read the terms, value one, and avoid the trap.
September 2, 2026TED, hypoparathyroidism, and achondroplasia each have a live 2026-2027 catalyst. BridgeBio owns two of the three, and its $15B price does not reflect it.
September 2, 2026Every investor reads the 10-K but skips the DEF 14A. Here is how to read the proxy like an activist: CEO pay vs burn, golden parachutes, governance red flags.
September 2, 2026uniQure submitted its AMT-130 BLA for Huntington's disease, the first gene therapy filing for the disorder. QURE fell 4.7% to $46.23; priority review requested.
September 2, 2026Roche licensed preclinical tri-specific SIM0660 from Simcere Zaiming for $75 million upfront and up to $1.53 billion in milestones, plus tiered royalties.
September 2, 2026Stoke and Biogen reported 4-year durability for zorevunersen in Dravet syndrome, with new sub-analyses on the severe seizures that drive SUDEP deaths.
September 2, 2026Teva's anti-IL-15 antibody TEV-408 met its Phase 2a primary endpoint in celiac disease, cutting gluten-induced gut damage at week 8. TEVA rose to $37.49.
September 2, 2026Telix completed BiPASS enrollment and aligned with the FDA on a pre-biopsy NDA. If approved, the market triples while TLX trades at a discount to Lantheus.
September 2, 2026The FDA accepted United Therapeutics' sNDA for inhaled Tyvaso in IPF, a fatal lung disease. UTHR closed at $492.02, decision expected in late April 2027.
September 2, 2026Envudeucitinib missed BICLA in the overall LUMUS population but posted a 24-point delta in IFNGS-high lupus. The psoriasis NDA in Q4 2026 is unaffected.
September 1, 2026Novartis paused eight rap-cel trials after three deaths and BMS followed. The field repriced overnight; here is which pure plays survive the higher bar.
September 1, 2026BridgeBio 42-month CMR data shows acoramidis may reverse cardiac damage in ATTR-CM, with 54% improving LV function vs 20% on placebo. Published in EJHF.
September 1, 2026Industrial activists want margin. Biotech activists want pipeline culls and M&A. How to spot the setup, trade the 13D, and why CAPR's fight can't fix a PDUFA.
September 1, 2026Biotech buyouts reprice in minutes. Here's how to read the deal spread, value cash vs stock vs CVR consideration, and size a tender-offer trade for investors.
September 1, 2026Everyone is waiting for the MS BTK race to resolve. It already did. Fenebrutinib swept three Phase 3 trials, Sanofi got rejected, and the moat held firm.
September 1, 2026Novartis halted eight rap-cel trials after three autoimmune patients died from a severe immune response; BMS paused its CAR-T programs too.
September 1, 2026 · Cell Therapy · $NVSNovartis' remibrutinib beat teriflunomide on relapse rate in two Phase 3 MS trials — the first BTK inhibitor with Phase 3 wins, clean liver.
September 1, 2026 · neuroscience · $NVSA $8.9 billion pre-revenue company is betting on a Q4 head-to-head against Merck's Capvaxive. The trial, the market math, and the risk for PCVX investors.
September 1, 2026Schrödinger, Recursion, Absci, and Relay all claim to be AI drug companies. Only one has a registrational Phase 3 asset. Here is the ranking by catalyst.
August 31, 2026Plozasiran cut pancreatitis 78% and triglycerides 79-81% in full SHASTA-3/4 data, pressing Tryngolza on safety and quarterly dosing before a year-end sNDA.
August 31, 2026 · $ARWRThe FDA approved PharmaEssentia's BESREMi for essential thrombocythemia, first new ET drug in nearly three decades. SURPASS-ET: 42.9% vs 6.0% anagrelide.
August 31, 2026The injectable GLP-1 duopoly is worth $1.26 trillion. The second wave, amylin analogs and oral GLP-1s, is where the multiples are sane. Ranked by catalyst.
August 31, 2026The FDA approved J&J's Stelara (ustekinumab) for pediatric ulcerative colitis Aug 28, making it the first non-TNF biologic across both pediatric IBD forms.
August 31, 2026Karyopharm submitted an sNDA for selinexor plus ruxolitinib in myelofibrosis, requesting Priority Review under accelerated approval. FDA decision in Q4.
August 31, 2026 · $KPTILilly will acquire Merida Biosciences for up to $2.875B, adding MER511, a Phase 1 autoantibody-degradation therapy for Graves' disease.
August 31, 2026 · Immunology · $LLYDMD, SMA, LGMD, and FSHD share one thesis: orphan pricing and a dense 2026 catalyst stack. Here are the six names ranked by nearest tradeable binary event.
August 31, 2026One million US patients, zero disease-modifying drugs. Tavapadon is now approved, prasinezumab is the last modifier standing, and the graveyard is full.
August 31, 2026Zenbexus and VEPPANU made degraders a proven class in 2026. The five pure-plays are ranked by catalyst, with Kymera priced and Nurix the best risk-reward.
August 31, 2026The market wrote off vaccines after COVID. Vaxcyte's Q4 PCV readout, Moderna's cancer vaccine, and the mRNA vs protein war, ranked by nearest catalyst.
August 31, 2026HERIZON-GEA-01's second interim met the overall survival co-primary endpoint for Ziihera plus chemo in first-line HER2+ GEA.
August 31, 2026 · oncology · $JAZZGLP-1 weight loss is 25-40% lean mass. Scholar Rock's apitegromab (Sept 30 PDUFA) leads the anti-myostatin fix while Lilly retreats on bimagrumab. Ranked.
August 30, 2026Osteoporosis, rare bone disease, and the elusive DMOAD converge in one under-covered market. Five bone-health stocks ranked by market cap and catalyst timing.
August 30, 2026The FDA accepted Nicox's NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma, and set an April 30, 2027 PDUFA date. Kowa is the U.S. licensee.
August 30, 2026Takeda's Orzeyful (oveporexton) won first FDA approval Aug 5. Alkermes, Centessa, and Axsome now race for narcolepsy type 2, hypersomnia, and cataplexy. Ranked.
August 30, 2026Praxis trades at $7.8B with relutrigine's PDUFA pushed to Dec 27. EMBOLD showed a 46% placebo-adjusted seizure cut, but the extension is a yellow flag.
August 30, 2026After the Lykos CRL, Lilly's $2.8B AtaiBeckley deal revived psychedelics. Six names ranked from Compass Pathways to MindMed by market cap and catalyst.
August 30, 2026SRRK trades at $7.04B with a Sept 30 PDUFA. SAPPHIRE hit its combined endpoint (p=0.019) but the 20 mg/kg dose missed. Approval is likely; the price is not.
August 30, 2026Teva is the stalking-horse bidder for BioXcel's BXCL501, an at-home agitation film with a Nov. 14 PDUFA date. The $57.5M upfront rides on timing milestones.
August 30, 2026Attruby grew 211% YoY to $222M in Q2, but a $15B valuation needs BBP-418, encaleret, and infigratinib to all hit. The launch is real; the multiple is not free.
August 29, 2026BMS's Zenbexus is the first CELMoD and the first myeloma drug approved on MRD negativity (41% vs 21%, p<0.0001). The class is real; the stock move is not.
August 29, 2026BioXcel Therapeutics filed Chapter 11 and named Teva stalking-horse bidder at $57.5M upfront plus $67.5M in milestones for BXCL501, ahead of the Nov 14 PDUFA.
August 29, 2026The race to replace opioids has one approved mechanism (NaV1.8), two mega-caps, and a $1.5B pure play with better-than-opioid data. Here is the ranking.
August 29, 2026Tudriqev's $450K launch is funded by a $150M raise, but the first oncolytic virus for melanoma must beat Amtagvi and T-VEC's ghost for 10K refractory patients.
August 29, 2026Three Elevidys deaths cut Sarepta from $120 to $16. At $21 and a $2.2B market cap, the DMD franchise trades at 1x revenue. The contrarian trade, honestly.
August 29, 2026Trutakna's accelerated approval hinges on ORIGIN 3's eGFR readout, due within weeks. A flat Phase 2b slope says convert; the proteinuria gap says be careful.
August 29, 2026Small molecule pills go generic the day the patent dies. Biologics keep their moat for decades. Here's the manufacturing reality behind the valuation.
August 28, 2026The funding winter ended, the IPO window is open, and M&A is at a record pace. But the 10-year yield is 4.66%. Here is where the cycle is and what to do.
August 28, 2026BioNTech is ending its Phase 2 autogene cevumeran trial in resected colorectal cancer after a data board flagged a survival imbalance between the two arms.
August 28, 2026A CRL drops your biotech 30% overnight. The resubmission playbook: Class 1 vs Class 2 review, realistic timelines, and the red flags that kill your odds.
August 28, 2026CTX310 held a 79% ANGPTL3 cut and a 53% LDL cut for a full year after one infusion. That answers the field's biggest question. Here's the trade for CRSP.
August 28, 2026Cytokinetics presented full ACACIA-HCM data at ESC 2026, the first positive Phase 3 result in non-obstructive HCM, with an sNDA filing planned for Q4.
August 28, 2026Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review: which designation actually moves a biotech stock, and which is just decoration.
August 28, 2026Biotech's real signal lives in SEC filings, not press releases. Read the 10-K, 10-Q, 8-K, and S-1 to find cash runway, FDA catalysts, and dilution early.
August 28, 2026The FDA cleared Mounjaro to lower heart attack, stroke, and cardiovascular death risk in adults with type 2 diabetes, a first for any GIP/GLP-1 drug ever.
August 28, 2026 · Cardiometabolic · $LLYFDA approved MIMRYLO (rusfertide) for erythrocytosis in polycythemia vera — the first hepcidin mimetic; VERIFY hit 76.9% vs 32.9%.
August 28, 2026 · Hematology · $PTGXGenentech paid $45M upfront for DualityBio's DUPAC platform to beat ADC payload resistance. It's a 0.3% blip on Roche's $354B cap. The trade is elsewhere.
August 28, 2026Rasonque's $39,800 monthly price is 2x Keytruda's, and RVMD now trades at a $47B cap before a single sales print. A historic launch, an unproven franchise.
August 28, 2026The money in biotech is made in the quiet months between readouts. How to track enrollment, data locks, abstracts, and interim looks to get positioned early.
August 28, 2026A clinical hold can drop a biotech stock 20-30% in a day. Learn what a hold is, full vs partial, why the FDA issues them, and how to read the 8-K and react.
August 28, 2026Tezspire met both co-primary endpoints in Phase 3 CROSSING for eosinophilic esophagitis, targeting a third epithelial indication.
August 27, 2026 · immunology · $AMGNBiosimilars erode originator biologics' revenue 30-50% at a time. How the BPCIA pathway works and how to spot a patent cliff before it hits your stock.
August 27, 2026Reverse mergers and SPACs look like IPOs but dilute differently. Check the cash, the ownership split, and the lock-up before you buy. Here is the setup.
August 27, 2026The going-concern note, the reverse split, the asset auction. Learn the runway math and four tripwires that show a biotech is heading to zero, before it does.
August 27, 2026Type A, B, and C FDA meetings run on a 30/60/75-day clock. Learn what each signals about approval odds and how to read a 'positive EOP2 meeting' honestly.
August 27, 2026Gilead's Bixlenvo won FDA approval Aug 27 as the first single-tablet regimen for suppressed adults on complex HIV regimens.
August 27, 2026 · Infectious disease / HIV · $GILDThe press release is marketing; the Q&A is where the truth lives. Seven qualitative tells from the Q2 2026 earnings cycle that preceded real stock moves.
August 27, 2026Most pre-PDUFA traders read the clinical data and skip the factory. Here's how to check CMC risk, Form 483s, and inspection status before a CRL costs you 40%.
August 27, 2026Vertex proved Nav1.8 works, but Latigo's LTG-001 beat hydrocodone where suzetrigine couldn't. At a $1.4B market cap, LTGO is the pure-play bet. Here is why.
August 27, 2026Roivant's LISRAYA (brepocitinib) is the first targeted therapy approved for dermatomyositis, clearing the FDA five weeks ahead of PDUFA.
August 27, 2026 · Immunology · $ROIVAbCellera's ABCL635 is the only pure play in the non-hormonal menopause race and Natera's $2.9B diagnostics franchise is the durable base. The shelf ranked.
August 27, 2026Ten drugs won FDA approval in 2026. Only Zenbexus and Fabhalta look like franchises, both mega-cap rounding errors. The pure plays remain unproven so far.
August 26, 2026Biohaven licenses its Kv7 epilepsy platform and lead drug opakalim to SK Biopharmaceuticals, which funds development toward a 2029 launch, for up to $795M.
August 26, 2026August saw over $1.1B in biotech IPOs, from Phase 3-ready Apnimed to Phase 1 narrative plays. Here is the quality split and what it means for valuations.
August 26, 2026Celcuity filed an sNDA to extend REVTORPYK (gedatolisib) to PIK3CA-mutant breast cancer after beating Novartis' Piqray in the VIKTORIA-1 mutant cohort.
August 26, 2026Fulcrum reverse-merges with migraine biotech Slate Medicines in an all-stock deal backed by a $245M PIPE, with the combined company set to trade as SLTE.
August 26, 2026FDA approved ViiV's Tivicay PD for newborns from birth — dolutegravir is the first integrase inhibitor cleared for this population.
August 26, 2026 · Infectious Disease · $GSKMadrigal's Rezdiffra posted $364M in Q2 sales, GSK and Zydus queue up PBC catalysts, and Bylvay's Phase 3 miss leaves biliary atresia to Mirum. Ranked.
August 26, 2026Cemdisiran, the first RNAi therapy for gMG, hits a November PDUFA with best-in-class data. The real beneficiary is Alnylam's platform, not Regeneron's stock.
August 26, 2026Enspryng's Oct 15 TED PDUFA is the first at-home challenger to Amgen's $1.9B Tepezza monopoly. Split Phase 3 data make this Amgen's loss, not Roche's win.
August 26, 2026Roche's Genentech licensed Hanmi's HM17321, a urocortin-2 analog that preserves lean muscle mass, for $190M upfront and up to $2.3B in milestone payments.
August 26, 2026Revolution Medicines' daraxonrasib won FDA approval in metastatic pancreatic cancer after nearly doubling median OS to 13.2 months.
August 26, 2026Ivonescimab beat Imfinzi on overall survival in first-line biliary tract cancer in the China-only HARMONi-GI1 trial, its fifth positive Phase 3 readout.
August 26, 2026Spyre's anti-TL1A antibody SPY072 hit its RA primary endpoint but missed the efficacy bar, so the company is pivoting to psoriasis and ulcerative colitis.
August 26, 2026IBD is a $20B+ market, five mechanisms. Merck's tulisokibart won the first Phase 3 TL1A readout. Skyrizi and Tremfya own the revenue. The swing is a pure play.
August 25, 2026FDA accepted GSK's Jemperli sBLA for stage II/III dMMR rectal cancer with Priority Review — a shot at the first organ-preservation label.
August 25, 2026PDUFA dates are biotech's most predictable catalysts. The run-up trade, the binary event, AdCom signals, sizing, and exit rules.
August 25, 2026Two Ziihera regimens cleared first-line HER2+ gastroesophageal adenocarcinoma with 26.4-month median OS — longest ever in the setting.
August 25, 2026 · oncology · $JAZZFDA approved J&J's IMAAVY (nipocalimab) as the first therapy for warm autoimmune hemolytic anemia; ~3x durable response rate vs placebo.
August 25, 2026 · Immunology · $JNJIntismeran met RFS and DMFS endpoints in INTerpath-001 — the first Phase 3 win for a personalized mRNA cancer vaccine. MRNA doubled.
August 25, 2026IgAN is crowded with three approvals and Vertex's Nov 30 PDUFA. FSGS remains a one-drug monopoly. Travere at $6B with 96% growth is the real kidney trade.
August 25, 2026September 2026 has 11 PDUFA dates: UX111 Sanfilippo gene therapy (Sept 19), zilganersen (Sept 22), and apitegromab (Sept 30) headline.
August 25, 2026Cobenfy's launch is muted at $63M a quarter. MapLight ML-007 is a binary bet. Neumora's navacaprant went 0-for-3 and died. The winner is Axsome's Auvelity.
August 25, 2026Rusfertide (MIMRYLO) won FDA approval Aug 28 for polycythemia vera, but PTGX at $10B had already priced it in. The label is what's left.
August 25, 2026The lung shelf: Vertex's $13B CF moat is unassailable, IPF's leader died and private Boehringer won, and PAH is a Merck side bet. One name is worth owning.
August 25, 2026FDA put REGENXBIO's RGX-121 on clinical hold after spine MRI findings; the Hunter syndrome gene therapy won't be resubmitted. RGNX fell 25%.
August 25, 2026 · Gene Therapy · $RGNXSkye Bioscience reverse-merges with Redx Pharma to form Fibrx Therapeutics, a $125M-backed fibrosis company led by RXC008 in fibrostenotic Crohn's disease.
August 25, 2026The FDA accepted United Therapeutics' ralinepag NDA for PAH, setting a June 24, 2027 decision. It would be the first once-daily oral prostacyclin for adults.
August 25, 2026Five dermatology catalysts ranked: Celldex barzolvolimab Phase 3 CSU readout can double or halve a $3.17B stock; four more catalysts round out the shelf.
August 24, 2026Five hematology catalysts ranked: Karyopharm selinexor in myelofibrosis is a $1.96 stock with a PDUFA trigger. Agios, Novo, and Immix round out the shelf.
August 24, 2026IgA nephropathy went from zero approved drugs to seven across five mechanisms in two years. Filspari and Vera's ORIGIN 3 readout are the two trades that matter.
August 23, 2026The FDA approved Mirum's Atebrioz (zilurgisertib) for FOP on September 25, one day early. This primer explains the PROGRESS data and the ALK2 inhibitor's place in a three-drug market.
August 23, 2026Rusfertide's 76.9% vs 32.9% VERIFY win made approval near-certain — and PTGX at $9.9B already reflected it. Now it's the royalty math.
August 23, 2026Pozelimab could be the first targeted therapy for VEXAS at its October 20 PDUFA. Approval looks near-certain, but it is a rounding error for an $86B company.
August 23, 2026Analyst price targets aren't forecasts. Learn to read the revision signal (upgrades, downgrades, consensus lag) instead of the number, which is just a snapshot.
August 22, 2026Three biotech ETFs can diverge 20 points in a year. Here's how XBI, IBB, and ARKG are built, which one fits your risk, and when to skip ETFs entirely.
August 22, 2026Lockup expirations are scheduled selloffs hiding in plain sight. Learn to find the date, read seller quality, and trade the overhang before it hits the stock.
August 22, 2026Activist Kaos Capital seeks Capricor (CAPR) board changes and an M&A review days before the deramiocel PDUFA. Shares have lost two-thirds since late July.
August 22, 2026While everyone chases obesity, the heart-disease and lipid pipeline is delivering approval-stage drugs. Here are 5 cardiometabolic catalysts ranked by risk.
August 22, 2026Efficacy gets the headlines, but safety data triggers most CRLs. How to read adverse events, SAEs, discontinuation rates, and black box warnings before you buy.
August 22, 2026The list price is not the revenue. Here's the gross-to-net waterfall step by step and why the gap between list and net decides whether a launch succeeds.
August 22, 2026From J&J's first oral IL-23 pill to MoonLake's IL-17 nanobody, five autoimmune catalysts ranked by risk-reward with real trial data and live market caps.
August 22, 2026The FDA issued a CRL for ITM 177Lu-edotreotide in GEP-NETs on Aug 7, citing only manufacturing and facility items. The Phase 3 COMPETE win still stands.
August 22, 2026Seven deaths and 100+ serious adverse events for Neurocrine Vykat XR in Prader-Willi have surfaced in FDA post-marketing data. NBIX stands by the drug.
August 22, 2026Wet AMD is a three-way fight, geographic atrophy is the next frontier, and gene therapy is entering retina. Here are 5 retina catalysts ranked by risk.
August 22, 2026The Curium-Lantheus $8B deal marked radiopharma's graduation to core oncology. Here is how to rank Novartis's Pluvicto, Telix, and the isotope supply chain.
August 22, 2026A biotech that needs cash can sell its future royalty stream instead of issuing shares. Here's how royalty financing works and how to invest on either side.
August 22, 2026Vogenx (VOGX) priced an $81M IPO at $13 and ran to $29.52 as mizagliflozin, an oral SGLT1 inhibitor for post-bariatric hypoglycemia, rode the Amylyx wave.
August 22, 2026Amylyx's avexitide cut Level 2/3 hypoglycemia 55% in Phase 3 LUCIDITY for post-bariatric hypoglycemia — no approved rival therapy exists.
August 21, 2026 · Metabolic · $AMLXargenx's ALKIVIA Phase 3 hit in myositis added $12B of market cap, but the dermatomyositis miss means brepocitinib owns that half. IMNM is the real prize.
August 21, 2026argenx's ALKIVIA Phase 3 hit its primary endpoint: efgartigimod beat placebo by 15.4 points on Total Improvement Score in myositis.
August 21, 2026 · Immunology · $ARGXEnhertu met its primary endpoint in DESTINY-Lung04 — first HER2-directed drug to beat standard of care in first-line HER2-mutant NSCLC.
August 21, 2026 · Oncology · $AZNBiotech has no revenue, so it plays different games: capitalized R&D, fudged cash runway, dilution. Here's where to find the 5 red flags in the footnotes.
August 21, 2026The headline says 'up to $2 billion.' The 8-K says $50 million upfront. Here's how to read the anatomy of a biotech licensing deal before you celebrate.
August 21, 2026BioMarin (BMRN) buys Alesta for $275M upfront, adding ALE1, a Phase 1/2a oral drug for hypophosphatasia that could rival AstraZeneca's injectable Strensiq.
August 21, 2026The FDA approved Bristol Myers Squibb's Zenbexus (iberdomide) for relapsed multiple myeloma, the first CELMoD. MRD-negative response hit 41% versus 21%.
August 21, 2026 · Oncology · $BMYCapricor (CAPR) will amend its deramiocel BLA to an upper-limb-only claim after the 9-3 AdCom vote, pushing the Aug 22 PDUFA back. The FDA may still reject it.
August 21, 2026CAR-T market: $8.95B in 2025 to a projected $19.25B by 2034. Three regulatory wins and manufacturing breakthroughs drive the move.
August 21, 2026 · OncologyDURAVYU missed its LUGANO Phase 3 primary endpoint and pivoted to an ad hoc analysis excluding 9 of 211 patients. Here is why that is not the same as a win.
August 21, 2026Werewolf (HOWL) reverse-merges with Ambros, which gets 71.7% plus a $150M PIPE to fund neridronate for CRPS-1. It will re-trade on Nasdaq as AMBX next year.
August 21, 2026Biotech is the most rate-sensitive sector. A 2% rate hike can cut a pre-revenue biotech's value by 40-60% with no bad news. Here's the discount-rate math.
August 21, 2026TAUKLARIFY beat Tauvid on accuracy (AUC 0.93 vs 0.86), but Lantheus is locked into a $102.50 Curium buyout. The tau win is CVR upside, not a tradable catalyst.
August 21, 2026Moderna and Merck's personalized cancer vaccine met its INTerpath-001 primary endpoint, cutting melanoma recurrence; MRNA closed up 177%.
August 21, 2026 · Oncology · $MRNAFDA approval is not the finish line. The first 90 days determine whether a drug becomes a commercial success or write-down. Here's what to track, week by week.
August 21, 2026The FDA approved Ultragenyx's Genglycos (DTX401), the first gene therapy for GSDIa. It cuts daily cornstarch needs and earned a priority review voucher.
August 21, 2026 · Rare Disease · $RAREThe FDA approved Regeneron's Pasatru (garetosmab) for FOP, a disorder where bone grows in muscle. It cut new bone lesions 90% in OPTIMA and reduced flare-ups.
August 21, 2026 · Rare Disease · $REGNEcopipam won Priority Review on clean Phase 3 data and a first-in-class D1 mechanism. It will likely be approved, but a $400M franchise won't move a $43B stock.
August 21, 2026Alzheimer's has four competing hypotheses. Two failed in Phase 2/3, amyloid is plateauing, and tau just cleared its first real hurdle in Biogen's diranersen.
August 11, 2026Four competing Alzheimer's approaches: two failed, one is plateauing, and the tau hypothesis just cleared its first real hurdle in Phase 3.
August 11, 2026FDA approvals and CRLs drop after the close. Here are the 3 after-hours patterns, the order types to use, and why the next open is where price is discovered.
August 11, 2026FDA approvals and CRLs drop 4-7 PM ET. The after-hours patterns, the order types to use, and why real price discovery is at the open.
August 11, 2026Biotech insiders buy for one reason: they expect gains. A framework for separating the $3M cluster buy from the $10K PR stunt, using BRVE and ZBIO case studies.
August 11, 2026Bispecific antibodies hit two targets simultaneously. Here are the three classes, how they differ as investments, and how to evaluate a bispecific catalyst.
August 11, 2026CAR-T is a $4B market. CAR-NK, TIL, and regenerative cell therapy are under $400M combined. Here is how each modality stacks up and which stocks lead.
August 11, 2026An FDA label defines a drug's real market -- what it treats, who it excludes, and the risks. Most investors skip it. Here are the six sections that matter.
August 11, 2026Biotech IPOs are the riskiest sector IPOs. This 5-question S-1 framework separates the 20% of winners from the 80% that trade below issue within 12 months.
August 11, 2026FDA briefing docs drop 2 days before every AdCom, 150 pages of regulatory opinion. Here are the 5 sections to read and how to decode the FDA's damning language.
August 11, 2026FDA briefing docs drop 2 days before every AdCom — the 5 sections to read, the 10 to skip, and how to decode polite-but-damning language.
August 11, 2026Sionna's SION-719 missed its sweat chloride target in a 15-patient Phase 2a CF trial with -1.0 mmol/L, far below the 5-7 mmol/L bar. VRTX rose 6% to $524.
August 11, 2026AbCellera's NK3R antibody cut moderate-to-severe hot flashes by 83% at week 4 with a single 600 mg dose. At $9.34, the stock added roughly $550M in market cap.
August 10, 2026AMR will kill 10 million annually by 2050 and cost $100 trillion. The antibiotics market is broken, but that is exactly where the asymmetric returns live.
August 10, 2026Casgevy proved gene editing works. The double-strand break is a liability. Base editing and prime editing fix that. Five stocks ranked for the next wave.
August 10, 2026Dilution is the silent killer of biotech returns. Learn the cash runway formula, the 3 signals a raise is coming, and how to position around it. Here is why.
August 10, 2026Biotech earnings are nothing like regular earnings. Ignore the GAAP EPS. Pipeline updates, cash runway, and guidance revisions are the numbers that matter.
August 10, 2026A great management team salvages a mediocre pipeline. A bad one destroys a great one. Here's how to separate the operators from the scientists in a suit.
August 10, 2026Standard screeners fail for biotech. Here are 7 filters — catalyst proximity, cash runway, insider clusters — that find tradeable setups, not dead money.
August 10, 2026Biotech buyouts deliver the highest single-day returns in the sector. Five patterns preceded the last 12 deals. Here is the 8-point screen for the next target.
August 10, 2026Sobi pays Innate $75M upfront for lacutamab, a first-in-class antibody for Sézary syndrome. The deal funds the Phase 3 trial toward accelerated approval.
August 10, 2026The IRA is the biggest structural change to biotech economics since Hatch-Waxman. Here is which companies face the most risk and how to screen for IRA exposure.
August 10, 2026Jazz will pay $820M upfront plus $500M milestones for Actio's KCNT1 inhibitor, aimed at a rare epilepsy with no approved therapies.
August 10, 2026 · CNS · $JAZZJazz will withdraw Zepzelca's second-line SCLC approval after LAGOON failed. Two confirmatory misses in six years close the accelerated approval chapter.
August 10, 2026Sonelokimab hit 42.1% ACR50 at Week 16 in biologic-naive psoriatic arthritis; the IL-17A/F Nanobody now has Phase 3 wins in two markets.
August 10, 2026 · rheumatology · $MLTXRevolution Medicines licensed Asian rights to four RAS(ON) inhibitors to BeOne, which funds a global Phase 3 trial. RVMD retains US, Europe, Japan, Korea.
August 10, 2026Silence Therapeutics' divesiran produced an 88% response rate vs 19% placebo in the Phase 2 SANRECO trial of phlebotomy-dependent PV. SLN jumped 42% intraday.
August 10, 2026Tenax's TNX-103 missed the 6-minute walk endpoint in the Phase 3 LEVEL trial for PH-HFpEF, a non-significant 3.5m gap vs placebo. TENX fell roughly 90% intraday.
August 10, 2026 · cardiovascular · $TENXMedical conferences move biotech stocks faster than most catalysts. The calendar, abstract rhythm, and six signals that separate data worth trading from noise.
August 10, 2026$236 billion in branded pharma revenue loses patent protection from 2026 to 2030. How to screen for biotech M&A targets before Big Pharma pays the premium.
August 9, 2026Most biotech investors own too many stocks or too few. Here's how to build a portfolio that survives CRLs, captures catalysts, and keeps you in the game.
August 9, 2026COGT faces two PDUFAs 30 days apart. GIST gets the attention but NonAdvSM has cleaner data, less competition, better risk-reward. The dual-catalyst playbook.
August 9, 2026December closes the year with four PDUFAs and two Phase 3 readouts. We rank six catalysts by tradeable binary risk-reward, sorting ghosts from moneymakers.
August 9, 2026Professional biotech short sellers look at your stock differently. Here are the 7 red flags they track, from trial design holes to cash runway cliffs.
August 9, 2026Iovance posted Q2 revenue of $99.3M, up 66%, on record Amtagvi sales. The TIL therapy for melanoma hit 56% gross margin and the stock surged 43% on the beat.
August 9, 2026IBTROZI hit $23.2M quarterly and leads ROS1 NSCLC. At $2.3B, safusidenib Phase 3 glioma data matters more than the January 2027 sNDA. Here is the setup.
August 9, 2026Otsuka VOYXACT delivered the largest eGFR treatment effect ever in an IgAN Phase 3 trial. The APRIL inhibitor showed +0.3 slope vs -4.2 for placebo at GlomCon.
August 9, 2026Pre-revenue biotechs have no sales, no earnings, and no P/E ratio. Here is a 5-question framework for deciding if the science is worth betting on. Here is why.
August 9, 2026Q1 2027 opens with four PDUFA dates: an sNDA label update, two first approvals, and one accelerated-to-full conversion. We rank each by tradeable risk-reward.
August 9, 2026Buying calls before a PDUFA date is the fastest way to lose money on a winning trade. Here is how IV crush works in biotech binaries and which strategies work.
August 9, 2026Arcturus (ARCT) terminated its $4.3B CSL vaccine deal, regaining KOSTAIVE rights. ARCT-032 inhaled mRNA for cystic fibrosis is now the investment thesis.
August 8, 2026Leqembi posted $184M in Q2 2026 sales, growing 15% YoY. But donanemab holds 55% market share. At $30.7B, BIIB prices in $1B+ Leqembi revenue. Here is why.
August 8, 2026BioVie stock dropped 50% after the bezisterim Phase 2 SUNRISE-PD readout in early PD. The primary endpoint was buried behind a self-constructed composite scale.
August 8, 2026FDA approved MRNA mFlusiva, first mRNA flu vaccine, 26.6% superior efficacy. Sanofi + GSK own the $6B+ market; it will not offset $782M losses at $23.6B.
August 8, 2026November 2026 drops five FDA decisions in 10 days: SVRA aPAP, BBIO LGMD2I, COGT GIST, GSK ALK, and a MRK ghost. Ranked by binary risk-reward. Here is the setup.
August 8, 2026BlossomHill Therapeutics priced an upsized $150M IPO at $16 for two oncology programs: BH-30643 in EGFR NSCLC and BH-30236 in AML. Shares trade as BLSM.
August 7, 2026BioMarin discontinued BMN 401 across all indications on August 6, writing off the $270M Inozyme deal. VOXZOGO raised 2026 guidance to at least $1 billion.
August 7, 2026Your immune system already knows how to kill cancer. CAR-T just removes the blindfold. Here's how engineered T-cells work, why they cost $400K, and which stocks to watch.
August 7, 2026Every blockbuster oncology drug needs a companion diagnostic, and the test maker gets paid every time the drug is used. The trade nobody talks about.
August 7, 2026Exelixis beat Q2 with Cabometyx at $570.6M and a Dec 3 zanzalintinib CRC PDUFA — but the $12.93B market cap already prices in both.
August 7, 2026Merck and Gilead ended the KEYNOTE-D46/EVOKE-03 trial after the E-DMC said Trodelvy plus Keytruda would not beat Keytruda alone on OS in first-line PD-L1+ NSCLC.
August 7, 2026GSK paid $10.6B for Nuvalent. Zidesamtinib delivered. Neladalkib heads to a Nov 27 PDUFA for TKI-pretreated ALK NSCLC. Data is real but GSK stock will not move.
August 7, 2026Latigo Biotherapeutics priced a $345.6M IPO at $18 for LTG-001, an oral Nav1.8 inhibitor with positive Phase 2 data. Shares trade today as LTGO on Nasdaq.
August 7, 2026Sanofi suspended SAR445399 in NCFB, the fourth pipeline program cut under new CEO Belén Garijo. The trial was halted July 29 for strategic reasons, not safety.
August 7, 2026A senior source denied any AstraZeneca-Bristol merger talks on Aug 5, three days after the FT reported preliminary discussions. AZN shares recovered 6%.
August 6, 2026 · Pharma · $AZN, BMYBraveheart Bio (BRVE) surged 66% to $29.80 on Nasdaq debut after a $382.5M IPO to fund Phase 3 trials of BHB-1893, a Hengrui-licensed cardiac myosin inhibitor.
August 6, 2026 · Cardiometabolic · $BRVEEvery biotech drug travels the same 8-stage journey from lab bench to pharmacy shelf. Know the stages, the failure rates, and how long each one takes before you invest.
August 6, 2026Bylvay failed its biliary atresia Phase 3, leaving Mirum's Q4 EXPAND readout as the only game in town — and $6.45B riding on the data.
August 6, 2026The FDA accepted Merck ENFLONSIA sBLA to expand RSV protection to high-risk children under 2. SMART trial showed antibody levels comparable to healthy infants.
August 6, 2026The FDA approved Moderna mFLUVISA on Aug 5, the first mRNA seasonal flu vaccine in the US. Phase 3 showed 26.6% higher efficacy vs standard-dose flu shots.
August 6, 2026 · Vaccines · $MRNANeuroscience trials run on validated scales: what ADAS-Cog, CDR-SB, UPDRS, PANSS, EDSS, and ALSFRS-R measure and a winning score.
August 6, 2026FDA approved Replimune's Tudriqev (RP1) plus nivolumab for anti-PD-1-resistant melanoma — the first oncolytic virus approval in melanoma.
August 6, 2026 · Oncology · $REPLSummit (SMMT) launched HARMONi-GU1, a Phase 2/3 trial of ivonescimab-Padcev in bladder cancer, its 16th registrational study ahead of the Nov 14 NSCLC PDUFA.
August 6, 2026Tarsus (TARS) will acquire Alkeus for $450M upfront, adding Phase 3 gildeuretinol for Stargardt disease, a rare retinal disorder with no FDA-approved treatment.
August 6, 2026 · Ophthalmology · $TARSArrowhead acquired a PRV to accelerate plozasiran's sHTG filing, but Ionis already has approval and $32M in 2026 TRYNGOLZA sales. Better data, later launch.
August 5, 2026BioMarin seeks to expand Voxzogo to children under 5 with achondroplasia. Feb 2027 PDUFA. BMRN at $59.99 with $11.7B market cap. Here is the risk-reward.
August 5, 2026 · Rare Disease · $BMRNCAR-T therapies cost $400K-$600K per patient because of a 3-6 week manufacturing chain. Allogeneic and in vivo CAR-T promise to cut costs 80%. Here is the investor guide.
August 5, 2026Enanta (ENTA) at $13.34 is a $387M micro-cap betting everything on EDP-978 in chronic urticaria. Phase 3 data in Q4 2026. Here is the risk-reward.
August 5, 2026 · Immunology · $ENTAGilead Q2 revenue grew 10% to $7.8B driven by HIV, but GAAP EPS swung to $(8.45) on $9.08/share in acquisition charges. Base business is healthy. Here is what matters.
August 5, 2026 · Infectious Disease · $GILDSemaglutide failed Alzheimer's Phase 3 EVOKE trials. Tirzepatide and retatrutide are next. The GLP-1 Alzheimer's hypothesis is dead as monotherapy. Here is what survives.
August 5, 2026 · Neuroscience · $NVOLiquid biopsy detects cancer DNA in blood instead of tissue. Natera, Guardant, Exact Sciences lead a $10B market. Here is the investor guide to the technology.
August 5, 2026 · Diagnostics · $NTRAEli Lilly Q2 revenue jumped 48% to $23B on Mounjaro and Zepbound. Retatrutide Phase 3 is complete with a BLA filing planned for Q1 2027. Here is what matters.
August 5, 2026 · Cardiometabolic · $LLYMerck Q2 revenue hit $16.6B but a $5.7B Terns acquisition charge produced a $(0.54) GAAP loss. Full-year EPS guidance was cut to $2.66-$2.76 from $5.04-$5.16.
August 5, 2026Moderna spent $6B+ on R&D since 2020 with zero non-COVID approvals. BioNTech pivoted to oncology. The mRNA platform economics do not add up. Here is why.
August 5, 2026 · mRNA · $MRNANuvation Bio (NUVB) at $6.40 seeks a first-line ROS1+ NSCLC label expansion for IBTROZI. Jan 4 PDUFA. Here is the pre-approval risk-reward analysis.
August 5, 2026 · Oncology · $NUVBNovo Nordisk Q2 sales hit DKK78.5B on semaglutide strength, but a DKK4B monlunabant write-down clouds the post-Wegovy pipeline. Here is what matters now.
August 5, 2026Novo Nordisk took DKK 6.3B in pipeline impairments including DKK 4B for monlunabant. Core GLP-1 franchise strong but beyond-GLP-1 pipeline is thinning fast.
August 5, 2026 · Cardiometabolic · $NVOPET imaging agents follow a unique FDA pathway as drug-device hybrids. Lantheus (LNTH) at $101.50 is the pure play. Here is the investor guide.
August 5, 2026 · Diagnostics · $LNTHPfizer beat Q2 estimates (EPS $0.77 vs $0.68) and raised guidance, but axed two obesity programs from its $10B Metsera pipeline. Only berobenatide remains.
August 5, 2026Pfizer beat Q2 estimates (EPS $0.77 vs $0.68) but axed MET-224o and a GIPR candidate from its $10B Metsera acquisition. Only berobenatide remains as the obesity bet.
August 5, 2026 · Cardiometabolic · $PFEADCT LOTIS-7 full results Q4: 89.8% ORR in DLBCL at $134M market cap. LOTIS-5 hit but 13.2% Grade 5 safety clouds the picture. Value trap or opportunity?
August 4, 2026The IL-31-focused biotech raised 45% more than originally planned, pricing 17 million shares at $17.00 ahead of its Nasdaq debut under ticker ATTO.
August 4, 2026 · Immunology · $ATTOCAR-T and bispecifics compete for the multiple myeloma market. CAR-T wins on efficacy, bispecifics on convenience. The sequencing data backs CAR-T first.
August 4, 2026Rhythm RM-718 showed -11.6% BMI in hypothalamic obesity across 7 patients at 16 weeks. The MC1R-sparing agonist targets better tolerability than setmelanotide.
August 4, 2026Three RSV vaccines are fighting for a $10B market. GSK has the best data and won early lead. Moderna's stock depends on mRESVIA. Pfizer's is a rounding error.
August 4, 2026VRTX povetacicept: 52% proteinuria reduction, Nov 30 PDUFA in four-player IgAN market. Strong RAINIER data but a $300M drug does not move a $119B stock.
August 4, 2026BNTX trades near cash as founders depart and a Sobi operator takes over the oncology pivot. The pipeline is worth $6.6B to the market. Here is the setup.
August 3, 2026LLY's next-gen KRAS G12C inhibitor earns Breakthrough Therapy in pancreatic cancer. At $1T market cap, the stock won't move on this. The pipeline does.
August 3, 2026Curium will buy Lantheus for up to $114.50/share ($102.50 cash plus $12 CVR) — up to $8B, the largest radiopharma deal yet.
August 3, 2026 · Radiopharma / M&A · $LNTHRare disease trials use natural history controls, tiny patient counts, and surrogate endpoints. Here is how to read the protocol and assess the risk profile.
August 3, 2026RCKT RP-A501 resumed after a fatal 2025 setback. Three patients dosed safely at a lower dose. The binary question for investors: will efficacy survive the cut?
August 3, 2026Supernus and Indivior will merge in an all-stock deal of equals: $2.2B revenue, 11 approved CNS drugs, $125M in cost synergies.
August 3, 2026 · CNS / M&A · $SUPNVertex (VRTX) posted $3.33B in Q2 2026 revenue, raised guidance, and got a Nov. 30 PDUFA for povetacicept in IgA nephropathy. The first non-CF pillar is near.
August 3, 2026AURA's bel-sarotmecan Phase 3 CoMpass trial targets early choroidal melanoma, a rare eye cancer with zero approved drugs. Data due H2 2027. Here is the setup.
August 2, 2026AstraZeneca held months of merger talks with Bristol Myers Squibb worth nearly $400B, the FT reported — the largest pharma deal ever floated.
August 2, 2026 · M&A · $AZNThree HIV cure strategies: CRISPR, bNAbs, latency reversal. Gilead and ViiV have no incentive to hurry. The framework for evaluating every cure claim you read.
August 2, 2026October 2026 brings two FDA decisions — bepirovirsen in HBV and INO-3107 in RRP — after Merck withdrew the I-DXd SCLC BLA. Ranked by market cap and binary clarity.
August 2, 2026Otsuka's VOYXACT became the first APRIL inhibitor to show 2-year eGFR stabilization in IgAN. The data supports its rolling sBLA for traditional FDA approval.
August 2, 2026Aclaris at $726M market cap has a Phase 2 anti-TSLP antibody with 94% EASI-75 in a single-arm trial. The placebo-controlled readout in Q4 2026 is binary.
August 1, 2026Autologous CAR-T is proven but manufacturing-capped. Allogeneic is the off-the-shelf promise that keeps failing on durability. How to read the difference.
August 1, 2026BridgeBio Oncology's pan-KRAS inhibitor enters Phase 1 with a confirmed PR in pancreatic cancer. At $648M vs RVMD's $40B, a cheap option on the KRAS race.
August 1, 2026Cancer vaccines are three technologies at different stages. MRNA and BNTX lead mRNA neoantigen vaccines with 49% RFS reduction. Here is which platform wins.
August 1, 2026Autologous CAR-T is proven but capped by manufacturing. Allogeneic is cheaper but persistence fails after 6-12 months. Here is how to evaluate both approaches.
August 1, 2026Keytruda generates $25B+ a year. Opdivo and Yervoy add billions more. How checkpoint inhibitors release the immune brake and why oncology trials use them.
August 1, 2026Gene therapies cost $2-4M per dose. The price is math: tiny patient populations, AAV manufacturing costs, and one-time dosing. Here is how to value the stock.
August 1, 2026Vaccines go through CBER not CDER, face a second commercial gate at ACIP, and measure prevention. Here is where the binary risk lives for vaccine stocks.
August 1, 2026IMMX autologous BCMA CAR-T shows a 95% complete response rate in AL amyloidosis. At $592M market cap, the stock is a binary bet on the September data update.
August 1, 2026Ex vivo editing made Casgevy at $2M per patient. In vivo CRISPR delivers the edit via injection. How it works and why it could transform biotech valuations.
August 1, 2026Selinexor missed PFS in XPORT-EC-042 endometrial cancer with HR 0.76 and CI crossing 1.0. Karyopharm now hinges on its August myelofibrosis sNDA filing.
August 1, 2026Karyopharm filed its selinexor plus ruxolitinib sNDA in myelofibrosis Aug 31, seeking accelerated approval; FDA decision possible H1 2027.
August 1, 2026mRNA vaccines aren't just COVID shots. Learn how the platform works, why lipid nanoparticles are the real moat, and what it means for biotech investors.
August 1, 2026REGENXBIO at $620M market cap is betting two Phase 3 trials can replace lifelong eye injections for 2M wet AMD patients. Q4 2026 topline data is binary.
August 1, 2026September brings two rare disease PDUFA dates at small-cap companies, plus a ghost catalyst from the GSK-Nuvalent deal. Here is the ranked trade setup.
August 1, 2026AbbVie Q2 2026: Skyrizi hit $5.5B to surpass Humira. The $10.9B Apogee deal buys a pre-Phase 3 IL-13 drug with 3-month dosing. Fairly valued at $257 a share.
July 31, 2026BMY pushed Cobenfy ADEPT and milvexian LIBREXIA-AF readouts to 2027. Slower enrollment resets the catalyst calendar. The iberdomide PDUFA on August 17 is next.
July 31, 2026REVTORPYK landed NCCN preferred Category 1 in 16 days, a signal that oncologists want this drug. At $4.3B with zero revenue, the science is ahead of the stock.
July 31, 2026A guide to reading clinical trial data: hazard ratios, confidence intervals, p-values, survival curves, and red flags separating real results from spin.
July 31, 2026Bepirovirsen delivers a 19% functional cure rate in hepatitis B. At $8.9B, IONS is the play, not GSK at $106B. PDUFA is October 26. Here is the full setup.
July 31, 2026Kiniksa bets KPL-387 can replace weekly Arcalyst with monthly dosing for recurrent pericarditis. At 7x sales, the stock prices in perfection. Here is the setup.
July 31, 2026Moderna's mRNA-1403 norovirus vaccine missed early-success criteria at a Phase 3 interim; shares fell 5.4% as a new cohort enrolls.
July 31, 2026 · mRNA · $MRNAMerck and Daiichi Sankyo withdrew the ifinatamab deruxtecan BLA for SCLC after the FDA said Phase 2 data don't support accelerated approval. Oct 10 PDUFA off.
July 31, 2026 · Oncology · $MRKModerna Q2 2026: $145M revenue, $782M loss. Norovirus vaccine missed Phase 3 interim. The August 5 flu PDUFA is now the entire thesis. Hold into the catalyst.
July 31, 2026Novo's ziltivekimab missed ZEUS with a MACE hazard ratio of 0.99; the IL-6 cardio thesis now needs HERMES and ARTEMIS to survive.
July 31, 2026 · biotech · $NVONovartis acquired Avidity for $12B. Del-brax just hit biomarker endpoints in FSHD with zero competition. But at $301B market cap, the BLA is a rounding error.
July 31, 2026FDA approved Pluvicto in PSMA+ metastatic hormone-sensitive prostate cancer 13 days early — roughly a fourfold larger patient population.
July 31, 2026 · Oncology / Radiopharmaceuticals · $NVSA drug for 500 patients at $500K/year is a $250M drug. Orphan pricing is a formula: exclusivity, value-based pricing, PRVs, and rare-disease revenue modeling.
July 31, 2026A biotech announced positive Phase 3 results and the stock is up 15%. Here is the framework for parsing endpoints, p-values, and safety before you act.
July 31, 2026Ionis and Alnylam are the two RNA platform leaders. After Alnylam's 29% guidance cut, the $18B market cap gap looks different. Five catalysts rank risk-reward.
July 31, 2026Roivant's brepocitinib could be the first approved dermatomyositis drug. At a $25B market cap, ROIV shareholders pay for the whole pipeline. Here is why.
July 31, 2026The FDA accepted Saol SL1009 resubmission for PDCD with a Dec. 30 PDUFA. No approved therapies exist. A Priority Review Voucher worth $100M+ is on the table.
July 31, 2026Sanofi beat earnings and raised guidance, but the stock fell 5.8% on €1B+ pipeline write-offs. At $43 and 1.9x sales, the discount is earned. The call: hold.
July 31, 2026Agios Q2: FDA granted Priority Review for the mitapivat sickle cell sNDA with a Nov 1 PDUFA. Cevidoplenib licensed and AG-236 siRNA advances to Phase 2/3.
July 30, 2026Alnylam Q2: Net product revenue hit $1.17B as AMVUTTRA crossed $1B for the first time. A TTR guidance cut to $4.2-$4.5B sent shares down 29% on July 30.
July 30, 2026Apnimed (APMD) upsized its IPO to 12M shares at $16, raising $192M for AD109, the first oral pill for obstructive sleep apnea.
July 30, 2026 · Sleep medicine / neuroscience · $APMDBMY's Growth Portfolio hit 58% of revenue at +15% growth — but the $129B market cap already prices in the CELMoD pipeline and then some.
July 30, 2026Q4 2026 has 21 FDA PDUFA dates. Five are investable binary events. The rest are mega-cap noise or foreign-listed. Here is the ranked playbook for investors.
July 30, 2026GILD's August 27 PDUFA for BIC/LEN is not a growth catalyst. It is Gilead competing with Biktarvy for the same patients. The stock will not move. Here is why.
July 30, 2026Five infectious disease catalysts ranked. GILD BIC/LEN cannibalizes Biktarvy, GSK bepirovirsen could cure HBV, and Atea HCV ignored at $370M. Here is why.
July 30, 2026Ionis posted Q2 revenue of $268M with a $115M net loss. Salanersen earned FDA Breakthrough Therapy for annual-dose SMA. Two FDA decisions are due by October.
July 30, 2026IONS at $8.9B with a Sept 22 PDUFA for zilganersen is not about Alexander disease revenue. It is about the antisense platform closing the gap with Alnylam.
July 30, 2026JNJ Rybrevant Faspro sBLA for head and neck cancer got FDA Priority Review. OrigAMI-4 showed 42% ORR with 15% complete responses. PDUFA expected in Q1 2027.
July 30, 2026J&J will pay $785M upfront and hold a $2.58B acquisition option on Sail Biomedicines' in vivo CAR-T platform for autoimmune disease.
July 30, 2026 · Cell Therapy · $JNJNBIX Q2 revenue jumped 39% to $959M with Ingrezza, Crenessity, and VYKAT XR all growing. The stock's fate hinges on two Phase 3 readouts in 2027. Hold for now.
July 30, 2026Pfizer's LITFULO met co-primary endpoints in two Phase 3 vitiligo trials — arriving second to a market AbbVie's Rinvoq just opened.
July 30, 2026 · dermatology · $PFEAMT-130 gene therapy showed 75% slowing of Huntington's at 36 months. BLA filing Q3 2026 under accelerated approval. At $2.78B, QURE is the purest HD play.
July 30, 2026FDA advisors voted 10-3 that RP1 plus nivolumab has favorable benefit-risk in anti-PD-1-resistant melanoma; REPL jumped 39% after hours.
July 30, 2026 · oncology · $REPLAlzheimer's trials fail 99% of the time. Five structural reasons, why Leqembi changed the bar but not the odds, and a framework for evaluating any catalyst.
July 30, 2026Gene therapy press releases mention AAV and lentiviral vectors. Learn what each means for disease targeting, manufacturing cost, and safety before you invest.
July 29, 2026ADCs are the hottest theme in oncology with $57B in pharma acquisitions. Here is how the three-part smart bomb works and why it matters for biotech investors.
July 29, 2026AstraZeneca's Ultomiris missed its primary endpoint in HSCT-TMA — the second Alexion Phase 3 failure in July after eplontersen.
July 29, 2026 · Rare Disease / Hematology · $AZNFrom Cogent's bezuclastinib to Savara's MOLBREEVI, seven biotech stocks with real PDUFA dates ranked by risk-reward. Two are explicit avoid calls. Here is why.
July 29, 2026Biogen Q2 2026: Growth Portfolio hit $1.06B, overtaking Legacy MS revenue for the first time. Leqembi reached $184M. Five registrational readouts ahead.
July 29, 2026Replimune at $449M is the only small-cap binary event in August. Moderna, Gilead, and Jazz are mega-cap noise. Here is the ranked playbook for investors.
July 29, 2026FDA advisors voted 9-3 that Capricor's HOPE-3 failed to show substantial evidence for deramiocel in DMD — the Aug 22 PDUFA leans rejection.
July 29, 2026 · cell-therapy · $CAPRNatera at $36B and Guardant at $19B are pricing in perfection. Lantheus at $6.7B is the value play. Here is the full diagnostics sector ranked for investors.
July 29, 2026Cabenuva cut viral rebound 7x vs daily pills in LATA adolescent HIV trial. GSK ViiV also showed OPERA real-world data and EXTEND 4M PrEP at AIDS 2026.
July 29, 2026 · infectious-disease · $GSKViiV 2-drug Dovato matched Gilead 3-drug Biktarvy in VOGUE at 89% vs 92% suppression. First head-to-head HIV data could shift first-line prescribing patterns.
July 29, 2026 · infectious-disease · $GSKZiihera won front-line GEA approval on Aug 25 with median OS of 26.4 months — still the strongest Phase 3 win in HER2+ GEA history.
July 29, 2026Oak Hill Bio raises $175M via RA Capital SPAC to advance rugonersen toward Phase 3 for Angelman syndrome. No FDA-approved treatments exist for the disorder.
July 29, 2026 · rare-disease · $OAKHPriority Review means a 6-month FDA clock; Standard Review means 10 months. Here is how the designation changes your catalyst timeline and trade planning.
July 29, 2026SVRA at $5.28 has zero revenue, one BLA, and a PDUFA that just got pushed to November 22. The IMPALA-2 data is real. The question is whether the FDA agrees.
July 29, 2026FDA cleared Viatris Gwyn Lo on July 29, a day before PDUFA. The low-estrogen weekly patch is restricted to women with BMI below 30 and launches later in 2026.
July 29, 2026Not every Phase 3 trial is pivotal. Here is how to identify a registrational study on ClinicalTrials.gov and why it changes the stock move when data reads out.
July 29, 2026ALT pemvidutide reduced heavy drinking and cut blood alcohol biomarker 38% in RECLAIM Phase 2. The GLP-1 class just entered addiction medicine. Here is why.
July 28, 2026Atea HCV pill matched Epclusa in C-BEYOND Phase 3: 93.9% vs 94.8% SVR, shorter 8-week course in most patients. Market shrugged. AVIR at $4.82. Here is why.
July 28, 2026Axsome AXS-12 (reboxetine) for cataplexy in narcolepsy gets a May 1 2027 PDUFA. Two Phase 3 trials met endpoints. First cataplexy-specific therapy if approved.
July 28, 2026Biotech stocks don't have earnings, so P/E is useless. Learn the three valuation methods that work: rNPV, peak sales multiples, and comparable analysis.
July 28, 2026BMS mezigdomide PDUFA May 13, 2027 after SUCCESSOR-2 showed 52% PFS risk reduction in myeloma; iberdomide (Zenbexus) approved Aug 13.
July 28, 2026CAR-T costs $465K per dose and cures blood cancers. Four 2026 catalysts from BMY, IMMX, ACET, and CRSP could each move stocks 30-50%. Here is the ranking.
July 28, 2026FDA accepted Cullinan/Taiho's NDA for zipalertinib in EGFR exon 20 insertion NSCLC. PDUFA is Feb 27, 2027, with 40% ORR in chemo-pre-treated patients.
July 28, 2026Clinical trial phases drive stock risk. Phase 1 rarely moves large caps, Phase 2 doubles micro-caps, Phase 3 is binary. Here is what to look for at each phase.
July 28, 2026The FDA accepted Cogent bezuclastinib plus sunitinib NDA in GIST with PDUFA November 30. PEAK trial PFS was 16.5 vs 9.2 months, first win in 20 years.
July 28, 2026Five CRISPR stocks ranked by platform moat and pipeline reality. Casgevy is ramping, Intellia is the real bet, and Editas is a warning sign for investors.
July 28, 2026Novo, Lilly, Roche, Viking, and Structure ranked by pipeline depth and valuation. Lilly is winning, Novo is chasing, and the oral pill war is the real fight.
July 28, 2026GSK beat Q2 with £8.41B revenue and launched a £1.9B cost-savings program to fund 20+ Phase III trial starts in 2026. Bepirovirsen PDUFA is October 26.
July 28, 2026GSK licensor Hansoh reported positive ARTEMIS-011 Phase 3 in relapsed osteosarcoma on July 28. It is the second Phase 3 win for the B7-H3 ADC after SCLC.
July 28, 2026ClinicalTrials.gov is the FDA registry where every registrational trial is posted. Learn which fields matter and catch companies spinning missed endpoints.
July 28, 2026FDA accepted Immunome NDA for varegacestat in desmoid tumors with April 28, 2027 PDUFA. RINGSIDE showed 84% risk reduction and 56% ORR. IMNM at $22.58.
July 28, 2026LEGN CEO Ying Huang stepped down July 24 with no permanent successor. CARVYKTI hit $657M in Q2 as J&J bispecific combo poses a new threat to the franchise.
July 28, 2026MapLight ML-007 met the primary PANSS endpoint in ZEPHYR but once-daily dosing failed. MPLT crashed 73% Monday, rebounded to $12.31 as the BID dose held.
July 28, 2026From Biogen tau-targeting data to Takeda narcolepsy first-in-class, 5 neuroscience catalysts ranked by risk-reward using real trial data and market caps.
July 28, 2026Oncology has 6 PDUFA catalysts in 2026. Most are at mega-caps where approval is a rounding error. COGT at $6.9B and BBIO at $16.5B are the two that move.
July 28, 2026FDA briefing docs called Replimune's RP1 data 'not interpretable' — then advisors voted 10-3 to back it and the FDA approved Aug 6.
July 28, 2026 · oncology · $REPLSarepta appointed Michael Severino, the former AbbVie R&D chief who built Rinvoq and Skyrizi, as CEO effective July 28. SRPT is down 91% from its 2024 high.
July 28, 2026FDA approved Takeda's Orzeyful (oveporexton) on Aug 5, 2026 — the first orexin agonist. Phase 3 showed >80% cataplexy reduction and near-normal wakefulness.
July 28, 2026Surrogate endpoints let drugs reach the market before anyone knows if they help. Here is how to spot one, why it matters for your stock, and when it fails.
July 28, 2026Supplemental filings expand an approved drug label to new uses. How sBLAs and sNDAs work, why approved more often, and why they move mega-cap stocks less.
July 28, 2026Argenx will buy Forte Biosciences for $77/share cash (~$2.2B), adding anti-CD122 antibody FB102 on vitiligo and celiac proof-of-concept data.
July 27, 2026 · immunology · $ARGXArrowhead completed YOSEMITE enrollment for zodasiran in HoFH. 70 patients enrolled, topping the 60-patient target. Study completion expected mid-2027.
July 27, 2026AstraZeneca's sonesitatug vedotin hit overall survival in CLARITY-Gastric01 in CLDN18.2+ gastric cancer, with a broader test threshold.
July 27, 2026 · oncology · $AZNFDA briefing docs say Capricor's HOPE-3 missed its primary endpoint, citing post-hoc changes; CAPR fell 65% before the AdComm vote.
July 27, 2026 · cell-therapy · $CAPRThe endpoint decides whether a biotech drug gets approved and whether the stock pops or drops. Here is how to read four endpoint types without getting fooled.
July 27, 2026GOSS plans to file an NDA for seralutinib despite missing its Phase 3 primary endpoint. At $0.20 and a $66M market cap, the market says the odds are near zero.
July 27, 2026Moderna and BioNTech face three catalysts in 2026 that could prove the mRNA platform extends beyond COVID. Here is the data behind the revaluation thesis.
July 27, 2026The FDA accepted Organogenesis's BLA for ReNu in knee OA with an April 24, 2027 PDUFA. It would be the first biologic for 31 million knee OA patients.
July 27, 2026The FDA accepted Pharvaris's NDA for deucrictibant IR in hereditary angioedema with an April 23, 2027 PDUFA. It would be the first oral on-demand HAE therapy.
July 27, 2026Six rare disease companies face PDUFA dates Aug to Dec 2026. Here is how I rank them by risk-reward, with the clinical data and market caps that matter.
July 27, 2026Stoke antisense drug upregulated NaV1.1 and cut seizures 85% in open-label data. The Phase 3 EMPEROR readout Q3 2027 is the binary catalyst for this $1.8B firm.
July 27, 2026A priority review voucher cuts FDA review from 10 months to 6 months and sells for $80M-$180M. Here's how to track PRV awards and trade the announcement.
July 27, 2026ADCs are oncology hottest theme. Pfizer, AbbVie, and Merck already paid up. Three 2026 catalysts remain and only one ticker offers pure exposure. Here is why.
July 26, 2026The FDA extended Beren Therapeutics' PDUFA for adrabetadex in infantile-onset Niemann-Pick type C to November 17, 2026. A major amendment triggered the delay.
July 26, 2026BLA or NDA tells you about manufacturing risk, exclusivity, and CRL odds. Here is how to identify which FDA filing a biotech is making before the PDUFA date.
July 26, 2026Lirafugratinib was approved September 23 as Lyrfigtu for FGFR2-driven cholangiocarcinoma — Elevar's first US approval, four days ahead of its Sept 27 PDUFA.
July 26, 2026Gene therapy had a brutal 2023-2024. Five 2026 catalysts could prove the science works. RARE at $2.65B and RGNX at $623M are the contrarian plays. Here is why.
July 26, 2026Biotech press releases spin trial data. Here is the framework to read past it: primary endpoints, p-values, confidence intervals, and the 60-second checklist.
July 26, 2026INOVIO's INO-3107 DNA medicine for recurrent respiratory papillomatosis faces an October 30 PDUFA. The FDA questioned the accelerated approval pathway.
July 26, 2026Signatera beat AMERK 90% to 55% in Merkel cell carcinoma. Natera's MRD moat is dominant, but at 13.5x forward revenue the stock leaves no margin for error.
July 26, 2026Arcus's casdatifan posted 15.1 months median PFS in late-line ccRCC. The data is solid, but Merck's Welireg generated $716M in 2025 and owns the HIF-2a class.
July 26, 2026SNY's venglustat hit p=0.007 in LEAP2MONO for GD3 neurological symptoms. At $43.35 with a Nov 25 PDUFA, the market is shrugging. Here is why that is right.
July 26, 2026ONO's tirabrutinib NDA for relapsed CNS lymphoma has a December 18 PDUFA. PROSPECT showed 67% ORR and 44% CR. No approved therapy exists for R/R PCNSL.
July 26, 2026Vanda's imsidolimab BLA for GPP has a December 12 PDUFA. GEMINI showed 53% clear skin vs 13% placebo and zero flares. Spevigo owns the two-drug market.
July 26, 2026Zydus Lifesciences' saroglitazar for PBC has a November 27 PDUFA date. Phase 3 showed 56.7% response vs 9.8% placebo. No US ticker; trades on Indian NSE.
July 26, 2026ACADIA won FDA Fast Track for remlifanserin in Alzheimer's disease psychosis, a condition with no approved therapies. RADIANT Phase 2 data read out as a near-miss on September 25.
July 25, 2026CHMP backed Enhertu plus pertuzumab as first-line HER2 metastatic breast cancer. DESTINY-Breast09 showed 40.7 vs 26.9 months median PFS. AZN closed at $169.26.
July 25, 2026EU approved AstraZeneca's Etcamah for ESR1-mutant breast cancer on SERENA-6; the FDA granted accelerated US approval in September.
July 25, 2026BridgeBio BBP-418 has a Nov 27 PDUFA for LGMD2I with clean Phase 3 data. At $16.5B market cap, BBIO stock already prices in approval — a hold, not buy.
July 25, 2026Biogen diranersen showed 50-65% tau reduction and 26% cognitive slowing in Phase 2 CELIA. But the primary endpoint missed. Phase 3 Alzheimer risk is real.
July 25, 2026FDA approved LEQEMBI IQLIK subcutaneous initiation dosing July 13 — the first anti-amyloid therapy with at-home dosing from day one.
July 25, 2026FDA issued a third CRL for Elevar's rivoceranib in liver cancer. The 23.8-month OS was never the problem. Manufacturing failures killed an approvable drug.
July 25, 2026GILD December 23 PDUFA for anito-cel tests a 7.8B acquisition thesis against J&J Carvykti dominance in a 20B myeloma market. Fourth-mover risk looms large.
July 25, 2026ISL/LEN Phase 3 ISLEND data show non-inferiority for the first once-weekly HIV pill. GILD at $129 is pricing in lenacapavir dominance. The risk is Merck.
July 25, 2026GSK discontinued camlipixant after CALM-2 failed, writing off the $2B Bellus Health buyout. The P2X3 class is now dead for chronic cough; Trevi rose 12%.
July 25, 2026The EMA's CHMP recommended GSK's Lynavoy (linerixibat), the first IBAT inhibitor for cholestatic pruritus in PBC, setting up EU approval within 67 days.
July 25, 2026Ipsen Phase 3 BOLD trial of Bylvay in biliary atresia missed its primary endpoint. The first global Phase 3 in the disease came up empty for IPSEY holders.
July 25, 2026The EMA's CHMP backed J&J's Icotyde (icotrokinra), the first oral IL-23 receptor antagonist, for moderate-to-severe plaque psoriasis in adults and teens 12+.
July 25, 2026JASMINE Phase 2: 53.6% SRI-4 at 52 weeks vs 39.7% placebo. Stelara is dying and argenx owns FcRn. Can nipocalimab carry JNJ immunology? JNJ is a hold.
July 25, 2026FDA granted De Novo authorization for JNJ's OTTAVA robotic surgery system. First table-integrated robot challenges ISRG da Vinci monopoly. JNJ at $263.40.
July 25, 2026Lilly will acquire AtaiBeckley for $2.8B upfront plus $1B in CVRs, adding BPL-003 for treatment-resistant depression. Largest psychedelic deal to date.
July 25, 2026Merck announced access plans for alimatravir on July 24. The monthly oral HIV PrEP pill is in Phase 3. Seven generic licenses span 129 LMIC countries.
July 25, 2026Kelun sac-TMT plus Keytruda beat chemo plus Keytruda in first-line PD-L1-negative NSCLC. First Phase 3 win for an ADC-ICI combination gives Merck a blueprint.
July 25, 2026The FDA approved belzutifan plus lenvatinib for advanced RCC on Sept 24, 2026, 10 days early. Our earlier analysis of the LITESPARK-011 PFS beat over cabozantinib.
July 25, 2026CHMP backed obicetrapib after 20 years of CETP failures. EU approval is real but the US path runs through PREVAIL. At $3.5B, NAMS prices in unearned CVOT win.
July 25, 2026Novo sued Eli Lilly on July 21 over ads claiming Zepbound beats Wegovy. The complaint cites outdated trial data comparing Lilly's top dose to Novo's lower dose.
July 25, 2026Pluvicto grew 43% in Q2 2026 to $651M. A Q3 mHSPC decision could quadruple the patient pool. At $155, Novartis is fairly valued with upside optionality.
July 25, 2026UX111 cuts CSF heparan sulfate 64% in Sanfilippo A. With a Sept 19 PDUFA, RARE at $2.65B prices in approval and a smooth launch. Here is why that is optimistic.
July 25, 2026REGENXBIO dosed the first patient in the NAAVIGATE trial of sura-vec gene therapy for diabetic retinopathy, unlocking a $100M AbbVie milestone payment.
July 25, 2026Roche discontinued acmopatide to prioritize enicepatide, which showed 22.5% weight loss with no plateau at 48 weeks. Carmot bet narrows to one obesity asset.
July 25, 2026The EMA's CHMP recommended Roche's Susvimo for wet AMD on July 24. The refillable eye implant cuts injections to twice a year. Already FDA-approved in the US.
July 25, 2026The EMA's CHMP backed Shionogi's Zokovea (ensitrelvir), the first oral antiviral for COVID-19 post-exposure prophylaxis, with EU approval expected in 67 days.
July 25, 2026SMMT at $13.66 prices the Nov 14 ivonescimab PDUFA at 50-50. HARMONi missed its primary OS endpoint, but a 0.76 HR in Western patients keeps the flip alive.
July 25, 2026Sanofi dropped amlitelimab in eczema on July 24, 2026 after Phase 3 data failed to clear the filing bar. Second OX40L drug shelved. SNY closed at $43.35.
July 25, 2026CRISPR's first approved therapy treated 500 patients and generated $43M in Q1 2026 revenue. Vertex prices in a steep ramp. Here is why the math is fragile.
July 25, 2026The FDA has a July 30 PDUFA date for Viatris Xulane LO, a weekly contraceptive patch cutting estrogen to 17.5 mcg from 35 mcg. VTRS closed at $17.24 on July 24.
July 25, 2026Accelerated approval lets the FDA approve drugs on surrogate endpoints before clinical benefit is proven. Here is how to tell if your stock approval is at risk.
July 25, 2026An FDA AdCom vote is the most predictable binary catalyst between a drug filing and its PDUFA date. Here is how to find AdComs, read the vote, and trade them.
July 25, 2026EMA CHMP rejected Zevra Miplyffa in Niemann-Pick disease type C. FDA approved the same drug in September 2024. Zevra seeks re-examination of the decision.
July 25, 2026Agios discontinued tebapivat in SCD after Phase 2 showed limited differentiation. Mitapivat sNDA has Nov 1 PDUFA. Novo Nordisk etavopivat gains ground.
July 24, 2026Agios discontinued tebapivat in sickle cell after Phase 2 showed no differentiation. Mitapivat Phase 3 RISE UP is the remaining SCD catalyst. AGIO at $36.28.
July 24, 2026FDA proposed withdrawing TAVNEOS after ADVOCATE data manipulation; Amgen submitted new data July 23 requesting a hearing.
July 24, 2026 · Immunology / Rare Disease · $AMGNArrowhead's plozasiran delivered 79-81% triglyceride cuts and zero pancreatitis events in the highest-risk subgroup of SHASTA-3/4.
July 24, 2026 · Cardiometabolic · $ARWRBridgeBio encaleret NDA for ADH1 accepted with May 2027 PDUFA. CALIBRATE data is clean, but $16B valuation prices in perfect launch for 1-in-70,000 prevalence.
July 24, 2026BridgeBio's encaleret NDA for ADH1, an ultra-rare calcium disorder with no approved treatments, was accepted by the FDA with a PDUFA date of May 8, 2027.
July 24, 2026The FDA's CTGTAC meets July 29 to review Capricor's deramiocel for DMD cardiomyopathy. A rescinded CRL and $1.1B market cap make this a binary catalyst.
July 24, 2026Celcuity won FDA approval for gedatolisib in PIK3CA wild-type breast cancer. The data is strong, stock fell 18%, and Novartis Piqray is the warning sign.
July 24, 2026Celldex discontinued barzolvolimab in prurigo nodularis after a Phase 2 miss despite profound mast cell depletion, putting the Q4 AD readout in question.
July 24, 2026Dyne BLA for z-rostudirsen in DMD is accepted with Priority Review. PDUFA January 21, 2027. Here is why the FORCE platform changes the exon-skipping math.
July 24, 2026Q3 2026 FDA PDUFA calendar with every confirmed date, ticker, drug, and indication. Track binary catalysts through September and position ahead of each PDUFA.
July 24, 2026FDA approved Keytruda plus Padcev for muscle-invasive bladder cancer. KEYNOTE-B15 showed 47% EFS and 35% OS risk reductions versus chemotherapy in 808 patients.
July 24, 2026 · Oncology · $MRKEMA CHMP backed Trodelvy plus Keytruda in PD-L1+ first-line metastatic TNBC, based on a 35% risk reduction from ASCENT-04. GILD closed at $130.86 on July 23.
July 24, 2026Biotech stocks do not trade like tech stocks. Learn how trial phases work, track FDA catalysts, and size positions for binary risk without losing your shirt.
July 24, 2026A practical framework for trading biotech PDUFA dates: when to enter, how to size for binary risk, read the AdCom, and when to exit on approval, CRL, or delay.
July 24, 2026Ionis and AstraZeneca eplontersen missed Phase 3 in ATTR cardiomyopathy. The largest ATTR-CM trial failed on background TTR stabilizers. IONS closed at $56.55.
July 24, 2026J&J's TECVAYLI plus TALVEY cut progression or death risk 89% (HR 0.11) in MonumenTAL-6 — lowest HR in any bispecific myeloma trial.
July 24, 2026 · Oncology · $JNJFDA approved MNKD FUROSCIX ReadyFlow on July 24, two days ahead of PDUFA. It delivers IV-equivalent furosemide in under 10 seconds for heart failure and CKD.
July 24, 2026 · Cardiovascular · $MNKDmFLUSIVA's 26.6% efficacy edge over standard flu shots is real but modest. At $22.6B market cap with $1.3B quarterly losses, Moderna needs more than a vaccine.
July 24, 2026Nektar rezpegaldesleukin enters Phase 3 in atopic dermatitis. Phase 2b hit every endpoint. At $2.3B and $69/share, NKTR prices in near-zero commercial success.
July 24, 2026FDA granted Novartis traditional approval for Fabhalta in IgA nephropathy — a stronger position than Trutakna's or Voyxact's accelerated.
July 24, 2026 · Nephrology · $NVSThe FDA has a July 29 PDUFA for Novo Nordisk's denecimig (Mim8) for subcutaneous prophylaxis in hemophilia A. Flexible dosing could challenge Roche's Hemlibra.
July 24, 2026Novo semaglutide failed EVOKE in Alzheimer's with a 0.06-point CDR-SB miss. The GLP-1 brain hypothesis is dead. NVO at $48.77 is a hold on the GLP-1 franchise.
July 24, 2026FDA approved Lytenava for wet AMD on July 24, five days early. First approved ophthalmic bevacizumab after three prior CRLs. OTLK at $1.32, cap $247M.
July 24, 2026 · Ophthalmology · $OTLKFDA approved Otsuka's SIMTRIYO (centanafadine) — the first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD, on July 24.
July 24, 2026 · neuroscience · $OTSKYPfizer's TALZENNA plus XTANDI cut rPFS risk 52% in HRR-mutated prostate cancer. At $25 and a 7% yield, the stock is priced for decline. This sNDA matters.
July 24, 2026FDA granted accelerated approval to Replimune's Tudriqev (RP1) plus nivolumab for advanced melanoma after two CRLs and a 10-3 AdComm vote.
July 24, 2026 · Oncology · $REPLRASolute 302 showed a 60% death-risk reduction in pancreatic cancer. The data is real. At $40B market cap, RVMD leaves little room for error on NDA timeline.
July 24, 2026Scribe Therapeutics (SCTX) priced an upsized IPO at $15/share, raising $128.7M for CRISPR cholesterol-lowering genetic medicines.
July 24, 2026 · Cardiometabolic · $SCTXFDA approved Sanofi Sarclisa Escena on-body injector for myeloma. First anticancer drug delivered via wearable device. Infusion reactions dropped 25% to 1.5%.
July 24, 2026Summit reported updated OS data showing a 24% death risk reduction in Western patients with EGFR-mutant lung cancer. The PDUFA date is November 14, 2026.
July 24, 2026FDA granted accelerated approval to Vera Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor to reduce proteinuria. A 46% reduction supports approval.
July 24, 2026FDA expanded Vertex Casgevy to ages 2+ on July 1, 2026. First CRISPR therapy for pediatric sickle cell and beta thalassemia, approved in 53 days under CNPV.
July 24, 2026 · Gene therapy · $VRTXVertex paid $10B for Crinetics as sole bidder, valuing Palsonify at 143x revenue. Endocrine platform led by atumelnant may justify the premium. VRTX is a hold.
July 24, 2026VRTX spent $10B on Crinetics as sole bidder. Six others passed, one capped value at $6B. Here is why the 10% drop says the market is right to be skeptical.
July 24, 2026A Complete Response Letter can drop a biotech stock 40% in a day. Here's what a CRL is, why the FDA issues them, and how to spot the risk before the date.
July 24, 2026A PDUFA date is the FDA's deadline to approve or reject a drug. Here is how to find upcoming dates, read the run-up, and avoid the most common mistake.
July 24, 2026FDA approved GSK's Jideytro (zidesamtinib) for treated ROS1+ lung cancer two months early, a week after the Nuvalent acquisition closed.
July 23, 2026 · Oncology · $GSKLilly's retatrutide hit primary endpoints in TRIUMPH-2 and TRIUMPH-3 with up to 22.6% weight loss; a Q1 2027 FDA filing is planned.
July 23, 2026 · Metabolic · $LLYFDA approved Merck's LIPFENDRA, the first oral PCSK9 inhibitor: 56-59% LDL-C cuts in Phase 3 could unlock the stalled PCSK9 market.
July 23, 2026 · Cardiometabolic · $MRKThe FDA approved Madrigal's resmetirom (Rezdiffra) on March 14, 2024 — the first-ever drug for MASH/NASH. Now the focus shifts to launch execution and label expansion.
July 22, 2026 · Rare Disease · $MDGLFDA approved Vertex's suzetrigine (Journavx) for acute pain — the first new pain class in 25 years. The chronic pain push is next.
July 21, 2026 · Rare Disease · $VRTXModerna's mRNA-4157 plus Keytruda cut melanoma recurrence 44%; a Nov 15 PDUFA could deliver the first approved mRNA cancer vaccine.
July 20, 2026 · mRNA · $MRNABiotech PRs spin trial data. How to read past the headline: primary endpoint, p-value, confidence intervals, and the fine print.
July 19, 2026 · GuideCRISPR's CTX112 (zugo-cel) is a next-gen allogeneic CAR-T for B-cell cancers and autoimmune disease — promising data, but no BLA filed yet.
July 18, 2026 · Gene Therapy · $CRSPAlnylam's zilebesiran showed sustained blood pressure reduction with twice-yearly dosing; the Phase 3 ZENITH outcomes trial is now starting.
July 17, 2026 · Rare Disease · $ALNYGilead's lenacapavir (Yeztugo) won PrEP approval with twice-yearly dosing; Bixlenvo cleared Aug 27 and a weekly pill PDUFA lands Feb 2027.
July 16, 2026 · Infectious Disease · $GILD